Keenova Therapeutics plc
Keenova Therapeutics plc (MNK): 9 pipeline candidates · ~16 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
16.1 months
D/E 1.80
Lead: Approved
9 candidates
N/A
5 buys · 0 sells (180d)
A transparent, data-derived signal for Keenova Therapeutics plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$965.7M
Quarterly Burn
$233.8M
Runway
16.1 mo
Revenue
$468.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| acthar gel | — |
| acthar gel | — |
| amitiza | — |
| amitiza | — |
| inomax | — |
| inomax | — |
| mydcombi | Approved |
| xiaflex | — |
| xiaflex | — |
Frequently asked questions
How many drug candidates are in Keenova Therapeutics plc's pipeline?
Keenova Therapeutics plc (MNK) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Keenova Therapeutics plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Keenova Therapeutics plc has approximately 16.1 months of cash runway.
Who is the CEO of Keenova Therapeutics plc?
Jonathan Zinman is the chief executive officer of Keenova Therapeutics plc (MNK).
Get the full picture on Keenova Therapeutics plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.